April 27, 2023
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The purpose of this notice is to inform applicants of a change to the Page Limits and Due Dates for PAR-23-024- Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- CT Optional)
Changes to the PAR are shown below:
Currently reads:
Key Dates
Open Date (Earliest Submission Date)
April 01, 2023
Letter of Intent Due Date(s)
30 days prior to the application due date.
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
Not Applicable | Not Applicable | May 01, 2023 | July 2023 | October 2023 | December 2023 |
Not Applicable | Not Applicable | May 01, 2024 | July 2024 | October 2024 | December 2024 |
Not Applicable | Not Applicable | May 01, 2025 | July 2025 | October 2025 | December 2025 |
Section IV.2 Content and Form of Application Submission
SF424(R&R) Cover
Proposed Project: Start date: For FY2024 enter 12/01/2023; For FY2025 enter 12/01/2024; For FY2026 enter 12/01/2025
PHS 398 Research Plan
Research Strategy: Upload the Essay here (Six pages total)
Describe your innovative vision for addressing a major problem related to HIV comorbidities, coinfections, and complications within the mission of one or more of the participating components. Explain the importance of this problem or challenge, and your qualifications to lead this project. No detailed scientific plan should be provided since the research plan is expected to evolve during the tenure of the grant. The essay should include the following sections in the order given with the headings as shown below:
Note: References are not required but if included must fit within the six-page limit. Figures and illustrations may be included but must also fit within the six-page limit. Information on collaborators may be included in the Essay and their names and affiliations should be listed in the Cover Letter.
Modified to Read (changes shown in bold italics):
Key Dates
Open Date (Earliest Submission Date)
August 01, 2023
Letter of Intent Due Date(s)
30 days prior to the application due date.
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
Not Applicable | Not Applicable | September 01, 2023 | November 2023 | January 2024 | April 2024 |
Not Applicable | Not Applicable | May 01, 2024 | July 2024 | October 2024 | December 2024 |
Not Applicable | Not Applicable | May 01 , 2025 | July 2025 | October 2025 | December 2025 |
Section IV.2 Content and Form of Application Submission
SF424(R&R) Cover
Proposed Project: Start date: For FY2024 enter 04/01/2024; For FY2025 enter 12/01/2024; For FY2026 enter 12/01/2025
PHS 398 Research Plan
Research Strategy: Upload the Essay here (Five pages total)
Describe your innovative vision for addressing a major problem related to HIV comorbidities, coinfections, and complications within the mission of one or more of the participating components. Explain the importance of this problem or challenge, and your qualifications to lead this project. No detailed scientific plan should be provided since the research plan is expected to evolve during the tenure of the grant. The essay should include the following sections in the order given with the headings as shown below:
Note: References are not required but if included must fit within the five-page limit. Figures and illustrations may be included but must also fit within the five-page limit. Information on collaborators may be included in the Essay and their names and affiliations should be listed in the Cover Letter.
All other aspects of this PAR remain unchanged.
Peter J. Perrin, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-451-3759
Email: [email protected]